Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1314 | EMPOWER Wiki | 0.71 |
| drug2781 | PLN-74809 Wiki | 0.71 |
| drug420 | Azinc Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003147 | Communication Disorders NIH | 0.71 |
| D016638 | Critical Illness NIH | 0.09 |
| D013577 | Syndrome NIH | 0.06 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
Hydroxychloroquine, a derivative of chloroquine (an antimalarial drug) with a weak immunosuppressive effect, is prescribed by some teams alone or in combination with azithromycin. No randomized controlled trials have demonstrated its efficacy, particularly in primary care in the early stages of the disease. However, currently available data suggest better efficacy if treatment is given early in the disease, before symptoms worsen. To date, the majority of COVID-19 patients treated in outpatient care, particularly in general practice, represent the majority of COVID-19 patients. It is essential to evaluate, in primary care, the efficacy and safety of hydroxychloroquine combined with azithromycin in Covid-19 patients in order to be able to implement this therapeutic strategy as soon as the first symptoms appear. We realize a randomized, controlled, open superiority trial, in 2 parallel groups (ratio 1:1).The main objective is to assess the efficacy of Hydroxychloroquine combined with azithromycin in COVID-19 patients in primary care, in add-on to standard of care, on unfavorable outcome defined by the onset of at least one of the following between D0 and D14: hospitalization, death or percutaneous O² saturation ≤ 92% in ambient air.
Description: Unfavorable outcome defined by the onset of at least one of the following between randomization and day 14: hospitalization, death or percutaneous O² saturation ≤ 92% in ambient air
Measure: Rate of patients with occurrence of an unfavorable outcome between randomization and day 14 Time: between randomization and day14Description: Ancillary virological study : evolution of viral load between day 0 and day 14, measured by the threshold cycle,Ct, with PCR on naso-pharyngeal swab
Measure: Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14 Time: between day 0 and day 14Description: Unfavorable outcome defined by the onset of at least one of the following between randomization and day 28: hospitalization, death or percutaneous O² saturation ≤ 92% in ambient air
Measure: Rate of patients with occurrence of an unfavorable outcome between randomization and day 28 Time: between randomization and day 28Description: Time to resolution of all COVID-19 symptoms : no COVID symptom for at least 48 hours without symptomatic treatment in previous 24 hours
Measure: The time to resolution of all COVID symptoms at day 14 Time: day 14Description: Time to resolution of all COVID-19 symptoms : no COVID symptom for at least 48 hours without symptomatic treatment in previous 24 hours
Measure: The time to resolution of all COVID symptoms atday 28 Time: day 28Description: Clinical status on a 7-point ordinal scale : Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.
Measure: Clinical status at day 14 Time: day 14Description: Clinical status on a 7-point ordinal scale : Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.
Measure: Clinical status at day 28 Time: day 28Description: Ancillary virological study : rate of patients with negative viral load at PCR on naso pharyngeal swab at day 8
Measure: Ancillary virological study : rate of patients with negative viral load at day 8 Time: day 8Description: Ancillary virological study : rate of patients with negative viral load at PCR on naso pharyngeal swab at day 14
Measure: Ancillary virological study : rate of patients with negative viral load at day 14 Time: day 14Multicenter, double blind, randomized clinical trial for high-risk patients over 18 years of age, symptomatic for COVID-19 infection, without any severity criteria
Description: Clinical deterioration throughout treatment
Measure: Clinical deterioration rate Time: 37 daysDescription: Evaluate the mortality and cause of death, at the end of treatment, at 28 days and 60 days from the start of treatment
Measure: Mortality and cause of death Time: 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports